Edition:
United States

Illumina Inc (ILMN.O)

ILMN.O on Nasdaq

210.67USD
20 Nov 2017
Change (% chg)

-- (--)
Prev Close
$210.67
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
837,410
52-wk High
$214.50
52-wk Low
$119.37

Chart for

About

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of... (more)

Overall

Beta: 0.75
Market Cap(Mil.): $30,757.82
Shares Outstanding(Mil.): 146.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.22 15.49
EPS (TTM): -- -- --
ROI: -- 9.98 11.95
ROE: -- 15.24 15.94

BRIEF-Illumina announces ‍introduction of its NextSeq 550Dx instrument

* Illumina Inc - ‍introduction of its NextSeq 550Dx instrument, co's second FDA-regulated and CE-IVD marked next-generation sequencing (NGS) system​

Nov 15 2017

BRIEF-Illumina reports Q3 GAAP earnings per share $1.11

* Illumina reports financial results for third quarter of fiscal year 2017

Oct 24 2017

BRIEF-Illumina files new patent infringement suit against Premaitha Health Plc

* Illumina Inc - ‍filed new patent infringement suit against Premaitha Health Plc in High Court of Justice, Chancery Division, Patents Court in UK Source text for Eikon: Further company coverage:

Sep 07 2017

'Liquid biopsy' spots early-stage cancers in blood: U.S. study

CHICAGO A test that scans blood for tumor-specific DNA identified early-stage cancer in more than half of 138 patients with the disease, U.S. researchers reported on Wednesday, marking a new milestone in the rush for so-called "liquid biopsies."

Aug 16 2017

'Liquid biopsy' spots early-stage cancers in blood -U.S. study

CHICAGO, Aug 16 A test that scans blood for tumor-specific DNA identified early-stage cancer in more than half of 138 patients with the disease, U.S. researchers reported on Wednesday, marking a new milestone in the rush for so-called "liquid biopsies."

Aug 16 2017

Illumina shares sparkle on strong demand for new gene tech

Shares of Illumina Inc surged nearly 14 percent on Wednesday, a day after the company raised its 2017 revenue forecast on strong demand for its new gene-sequencing technology.

Aug 02 2017

CORRECTED-UPDATE 1-Illumina shares sparkle on strong demand for new gene tech

Aug 2 Shares of Illumina Inc surged nearly 14 percent on Wednesday, a day after the company raised its 2017 revenue forecast on strong demand for its new gene-sequencing technology.

Aug 02 2017

Illumina shares sparkle on demand for new gene tech

Aug 2 Shares of Illumina Inc surged nearly 12 percent on Wednesday, a day after the company raised its full-year revenue forecast on higher-than-expected demand for its new gene-sequencing technology.

Aug 02 2017

BRIEF-Illumina Q2 earnings per share $0.87

* Illumina reports strong financial results for second quarter of fiscal year 2017

Aug 01 2017

Illumina notches win in prenatal testing patent fight

A federal appeals court on Tuesday revived a patent on fetal diagnostic testing that Illumina Inc has accused rival Sequenom Inc of infringing.

Jun 27 2017

Earnings vs. Estimates